Genetic Newborn Screening for Retinoblastoma: A Belgian Initiative Baby Detect.

Area of Science:

• Genetics
• Oncology
• Pediatrics

Background:

• Retinoblastoma is a serious childhood cancer often caused by germline RB1 mutations.
• Delayed diagnosis of RB1 mutations leads to vision loss and necessitates aggressive treatment.

Purpose of the Study:

• To establish a newborn screening test for early-onset, treatable genetic conditions using targeted next-generation sequencing.
• To specifically evaluate the feasibility and impact of screening for RB1 mutations in newborns.

Main Methods:

• Development of a comprehensive gene panel (405 genes, 165 conditions) including RB1.
• Utilizing targeted next-generation sequencing for population-wide newborn screening.

Main Results:

• The RB1 gene panel identifies mutations linked to retinoblastoma, a significant cause of childhood blindness.
• Early detection of germline RB1 mutations at birth can improve patient outcomes and reduce treatment intensity.

Conclusions:

• Newborn screening for RB1 mutations represents a novel approach to retinoblastoma patient care.
• Implementing this screening at a national scale could significantly enhance functional and anatomical outcomes for affected children.